- Home
- PAYS vs ALDX Comparison
PAYS vs ALDX Comparison
Compare PAYS & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYS
- ALDX
- Stock Information
- Founded
- PAYS 2001
- ALDX 2004
- Country
- PAYS United States
- ALDX United States
- Employees
- PAYS N/A
- ALDX N/A
- Industry
- PAYS Business Services
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- PAYS Consumer Discretionary
- ALDX Health Care
- Exchange
- PAYS Nasdaq
- ALDX Nasdaq
- Market Cap
- PAYS 303.3M
- ALDX 314.6M
- IPO Year
- PAYS 1998
- ALDX 2014
- Fundamental
- Price
- PAYS $5.23
- ALDX $4.93
- Analyst Decision
- PAYS Strong Buy
- ALDX Strong Buy
- Analyst Count
- PAYS 4
- ALDX 2
- Target Price
- PAYS $8.06
- ALDX $9.50
- AVG Volume (30 Days)
- PAYS 354.9K
- ALDX 644.4K
- Earning Date
- PAYS 11-12-2025
- ALDX 11-06-2025
- Dividend Yield
- PAYS N/A
- ALDX N/A
- EPS Growth
- PAYS N/A
- ALDX N/A
- EPS
- PAYS 0.12
- ALDX N/A
- Revenue
- PAYS $68,539,381.00
- ALDX N/A
- Revenue This Year
- PAYS $35.44
- ALDX N/A
- Revenue Next Year
- PAYS $21.93
- ALDX $63.48
- P/E Ratio
- PAYS $43.55
- ALDX N/A
- Revenue Growth
- PAYS 27.84
- ALDX N/A
- 52 Week Low
- PAYS $1.80
- ALDX $1.14
- 52 Week High
- PAYS $8.88
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- PAYS 41.38
- ALDX 40.91
- Support Level
- PAYS $5.06
- ALDX $4.85
- Resistance Level
- PAYS $5.33
- ALDX $5.27
- Average True Range (ATR)
- PAYS 0.22
- ALDX 0.27
- MACD
- PAYS -0.05
- ALDX -0.04
- Stochastic Oscillator
- PAYS 15.87
- ALDX 27.40
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.